Portal de investigación
Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos”.
Datos básicos
- Código:
- CLIN-52120-463
- Protocolo:
- CLIN-52120-463
- EUDRACT:
- 2023-504827-17-00
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2023
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.
Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin
Article. 10.1016/j.farma.2024.08.002. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.
Pérez-Alenda S; (...); Núñez-Cortés R
Article. 10.1111/hae.14988. 2024
Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom
Diaz-Insa, Samuel; (...); Goadsby, Peter J.
Article. 10.1155/ane/4714514. 2024
Cluster headache. Are there differences by gender?
Olivier, M. A.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.
Megias-Vericat, Juan E; (...); Yan, Songkai
Article. 10.1080/13696998.2025.2474886. 2025
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group
Garcia-Ulla, J.; (...); Irimiao, P.
Article. 10.1016/j.nrl.2023.06.003. 2025
Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group.
Garcia-Ull, J; (...); Irimia, P
Practice Guideline. 10.1016/j.nrleng.2024.02.009. 2024
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes.
Mínguez-Olaondo A; (...); Díaz-Insa S
Article. 10.33588/rn.7802.2023176. 2024
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study.
Díaz Insa S; (...); Núñez M
Article. 10.1007/s40122-024-00586-6. 2024
Onabotulinum Toxin A (OnA) as a preventive treatment for non-migraine headaches: a retrospective analysis
Nieves Castellanos, C.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Predictors of =50% and =75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
Caronna, E.; (...); Pozo-Rosich, P.
Meeting Abstract. 2024
Psychological intervention in refractory chronic migraine patients
Zambrano Camina, M.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E; (...); Pozo-Rosich P
Article. 10.1136/jnnp-2023-333295. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024